This is probably the better benchmark for this trial, notwithstanding that it will be the depth of response (the durability) that will be the point of difference that CORE NK is expected to add. This is a quick summary that Grok puts forth:
- Forums
- ASX - By Stock
- Ann: ADVENT-AML Phase 1B clinical trial update
CHM
chimeric therapeutics limited
Add to My Watchlist
0.00%
!
0.4¢

This is probably the better benchmark for this trial,...
Featured News
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
|
|||||
Last
0.4¢ |
Change
0.000(0.00%) |
Mkt cap ! $8.060M |
Open | High | Low | Value | Volume |
0.5¢ | 0.5¢ | 0.4¢ | $15.69K | 3.919M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
26 | 21936206 | 0.4¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
0.5¢ | 24685267 | 27 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
26 | 21936206 | 0.004 |
38 | 23301940 | 0.003 |
15 | 12300508 | 0.002 |
10 | 59600000 | 0.001 |
0 | 0 | 0.000 |
Price($) | Vol. | No. |
---|---|---|
0.005 | 22760116 | 26 |
0.006 | 13828910 | 16 |
0.007 | 5660001 | 5 |
0.008 | 8542434 | 6 |
0.009 | 2767672 | 5 |
Last trade - 16.10pm 13/06/2025 (20 minute delay) ? |
Featured News
CHM (ASX) Chart |